Real-World Use of Fedratinib for Myelofibrosis Following Ruxolitinib Failure

A retrospective patient chart review was conducted to examine the real-world patient characteristics, treatment patterns, and clinical outcomes of myelofibrosis (MF) patients treated with fedratinib following ruxolitinib failure in US clinical practice. The study included 150 eligible patients, with data abstracted by 24 physicians. The majority of the patients were male (55.3%), White (68.0%), and had a median age of 68 years at MF diagnosis. The median duration of ruxolitinib therapy before switching to fedratinib was 7.6 months.

At the initiation of fedratinib treatment, 88.0% of patients had a palpable spleen, with a mean spleen size of 16.0 cm. Significant reductions in spleen size were observed, decreasing by 19.4% to 13.2 cm at month 3 and by 53.4% to 7.2 cm at month 6 of fedratinib treatment. Additionally, 26.8% of patients achieved a spleen reduction of ≥50% by month 6. The study also noted a significant decrease in the mean number of symptoms at both month 3 and month 6 of treatment.

The findings suggest that fedratinib offers spleen and symptom benefits for MF patients who have previously been treated with ruxolitinib, highlighting its potential as an effective treatment option following ruxolitinib failure.